imatinib
novartis
['imatinib', '#gi']
study on the remission of patients with oligo-metastatic #gist after discontinuing #imatinib. results showed 5 out of the 12 patients sustained complete remission 42 months after discontinuing imatinib. patients that restarted imatinib attained a 2nd treatment response.
#asco2022 
Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.